A 7-day course of vonoprazan and low-dose amoxicillin dual (VA-dual) therapy proves useful in the first-line treatment of Helicobacter pylori infection, especially in regions with high clarithromycin resistance, yielding an acceptable eradication efficacy that is similar to that achieved with vonoprazan-based triple (VAC-triple) therapy, according to the results of an open-label trial.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Treatment with indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily in patients with chronic obstructive pulmonary disease (COPD) who have not received long-acting bronchodilators (LABD) leads to improvements in lung function, daily symptoms, dyspnoea, health-related quality of life and rescue medication compared with use of long-acting muscarinic antagonists (LAMA), a study has shown.
In the management of infants born with moderate hypoglycaemia, a strategy of initiating treatment at a lower glucose concentration proves noninferior to a traditional threshold of 47 mg/dL in terms of preventing brain injury, according to the results of the HypoEXIT* trial.
The single-agent ibrutinib demonstrates significant and durable survival benefits compared with chlorambucil in the first-line treatment of older patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), including those with high-risk prognostic features, according to 5-year data from the RESONATE-2 study.
The combination of pinaverium bromide 100 mg plus simethicone 300 mg is effective in the treatment of bloating (PB+S) and abdominal pain in patients with active irritable bowel syndrome (IBS), a study has shown. The effect of combined therapy on the frequency of stool consistency was significant in IBS with constipation (C) and mixed-type (M) IBS.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Pharmacy associations are opposing the federal government’s sudden second revision of the retail price for three-ply medical grade face masks from RM2.00 to RM1.50 on short notice without prior consultation with stakeholders.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.